QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:KMPH

Zevra Therapeutics - KMPH Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$4.12
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Zevra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$17.25 Price Target
Short Interest
Healthy
4.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Zevra Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$55,369 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

414th out of 986 stocks

Pharmaceutical Preparations Industry

193rd out of 477 stocks


KMPH stock logo

About Zevra Therapeutics (NASDAQ:KMPH) Stock

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Zevra Therapeutics Begins Trading as ZVRA
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Breakeven On The Horizon For KemPharm, Inc. (NASDAQ:KMPH)
KemPharm Enhances Senior Management Team
KemPharm Third Quarter 2022 Earnings: Misses Expectations
See More Headlines
Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Company Calendar

Last Earnings
3/30/2022
Today
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Book Value
$3.63 per share

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Key Executives

  • Richard W. PascoeRichard W. Pascoe
    Chief Executive Officer & Director
  • Travis C. MickleTravis C. Mickle
    President & Director
  • R. LaDuane CliftonR. LaDuane Clifton
    Chief Financial Officer, Secretary & Treasurer
  • Sven Guenther
    Chief Scientific Officer
  • Daniel Gallo
    Senior Vice President-Medical Affairs













KMPH Stock - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KMPH shares.
View KMPH analyst ratings
or view top-rated stocks.

What is Zevra Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year price objectives for Zevra Therapeutics' shares. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $17.25 in the next year.
View analysts price targets for KMPH
or view top-rated stocks among Wall Street analysts.

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:KMPH) announced its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

What ETF holds Zevra Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,480 shares of KMPH stock, representing 0.37% of its portfolio.

What other stocks do shareholders of Zevra Therapeutics own?
When did Zevra Therapeutics IPO?

(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is Zevra Therapeutics' stock symbol?

Zevra Therapeutics trades on the NASDAQ under the ticker symbol "KMPH."

Who are Zevra Therapeutics' major shareholders?

Zevra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (1.43%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.90%), Retirement Planning Co of New England Inc. (0.86%), Susquehanna International Group LLP (0.00%) and Mystic Asset Management Inc. (0.51%). Insiders that own company stock include David S Tierney, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Tamara A Seymour and Travis C Mickle.
View institutional ownership trends
.

How do I buy shares of Zevra Therapeutics?

Shares of KMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Zevra Therapeutics make?

Zevra Therapeutics (NASDAQ:KMPH) has a market capitalization of $0.00 and generates $10.72 million in revenue each year.

How can I contact Zevra Therapeutics?

Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:KMPH) was last updated on 3/23/2023 by MarketBeat.com Staff